Takayuki Nagasawa, Tadahiro Shoji, Eriko Takatori, Yoshitaka Kaido, Masahiro Kagabu, Dai Shimizu, Tatsuhiko Shigeto, Tsukasa Baba, Toru Sugiyama, Yoshihito Yokoyama. A Phase II Study of S-1 plus Oxaliplatin for Patients with Recurrent Non-Squamous Cell Carcinoma of the Uterine Cervix (Tohoku Gynecologic Cancer Unit: TGCU206 Study). Cancers. 2023. 15. 21. 5201-5201
Tsukasa Baba, Masafumi Koshiyama, Masahiro Kagabu, Yoshiki Mikami, Sachiko Minamiguchi, Suzuko Moritani, Mitsuya Ishikawa, Aikou Okamoto, Yasuhisa Terao, Toru Nakanishi, et al. Ovarian serous borderline tumors with recurrent or extraovarian lesions: a Japanese, retrospective, multi-institutional, population-based study. International journal of clinical oncology. 2023. 28. 10. 1411-1420
Hidehiko Akashi, Nozomi Yachida, Haruka Ueda, Manako Yamaguchi, Kaoru Yamawaki, Ryo Tamura, Kazuaki Suda, Tatsuya Ishiguro, Sosuke Adachi, Yoshikazu Nagase, et al. SLFN11 is a BRCA independent biomarker for the response to platinum-based chemotherapy in high-grade serous ovarian cancer and clear cell ovarian carcinoma. Molecular cancer therapeutics. 2023
Marina Abe, Tadahiro Shoji, Yohei Chiba, Eriko Takatori, Yoshitaka Kaido, Takayuki Nagasawa, Masahiro Kagabu, Fumiaki Takahashi, Takeshi Aida, Tsukasa Baba. Efficacy and Safety of Platinum-based Chemotherapy With Bevacizumab Followed by Bevacizumab Maintenance for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer During PARP Inhibitor Therapy: A Multicenter Retrospective Study. Anticancer research. 2023. 43. 3. 1265-1272
Masahiro Kagabu, Tsukasa Baba. Immunotherapy for Gynecologic Cancer. 2023. 1-19
Mitsuya Ishikawa, Ryo Kitagawa, Taro Shibata, Hideki Tokunaga, Takashi Iwata, Shin Nishio, Toshio Takada, Masahiko Mori, Koji Horie, Wataru Kudaka, et al. A randomized phase II/III trial of conventional paclitaxel and carboplatin with/without bevacizumab versus dose-dense paclitaxel and carboplatin with/without bevacizumab, in stage IVB, recurrent, or persistent cervical carcinoma (JCOG1311): Results of the phase II part. JOURNAL OF CLINICAL ONCOLOGY. 2020. 38. 15
